Filing Flows › Eton Pharmaceuticals (ETON) › Q2 2026
Eton Pharmaceuticals (ETON) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Eton Pharmaceuticals (ETON) reported revenue of $37.6M for the second quarter 2026 (Q2 2026), +99% from a year earlier and +55% from the quarter before. Operating margin was 34.0%, net earnings $11.6M (30.8% of revenue).
Eton Pharmaceuticals, Q2 2026: revenue $37.6M (+99% year over year), operating margin 34.0%, net earnings $11.6M, operating cash flow $7.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $37.6M | +55% | +99% |
| Gross profit | $25.4M | +72% | +113% |
| Operating profit | $12.8M | +430% | — |
| Net earnings | $11.6M | +645% | — |
| Operating cash flow | $7.3M | -2% | -9% |
What changed
Revenue was $37.6M in Q2 2026, up 99% year over year and up 55% from the previous quarter.
Gross margin was 67.6%, up 4.6 points from Q2 2025. Operating profit was $12.8M, a 34.0% margin (up 41.8 points year over year). Operating expenses fell 6% while revenue rose 99%. The fastest-growing cost line was General & admin (+20%). Net earnings were $11.6M. The effective tax rate was 1.2%.
Operating cash flow was $7.3M (down 9% year over year), 63% of net earnings. Non-cash charges added back $1.4M of depreciation and amortization and $1.5M of share-based compensation. Working capital and other items used $7.2M. Capital expenditures of −$5K left free cash flow of $7.3M.
Questions
What was Eton Pharmaceuticals' revenue in the second quarter 2026?
Eton Pharmaceuticals (ETON) reported revenue of $37.6M for the second quarter 2026 (Q2 2026), +99% from a year earlier and +55% from the quarter before.
Was Eton Pharmaceuticals profitable in the second quarter 2026?
Operating profit was $12.8M (34.0% of revenue) and net earnings $11.6M.